

Board of Directors

President

Jeffrey Chamberlain, PhD
University of Washington

President-Elect

Paula Cannon, PhD
University of Southern California

Vice President

Terence R. Flotte, MD
University of Massachusetts
Chan Medical School

Secretary

Isabelle Riviere, PhD
Takeda

Treasurer

Federico Mingozzi, PhD
Spark Therapeutics

Directors

Aravind Asokan, PhD
Duke University

Daniel E. Bauer, MD, PhD

Boston Children's Hospital +
Harvard University

Hildegard Büning, PhD

Hannover Medical School

Lindsey George, MD

Children's Hospital of Philadelphia

Punam Malik, MD

Cincinnati Children's Hospital

Kah-Whye Peng, PhD

Mayo Clinic

Maria-Grazia Roncarolo, MD

Stanford University

Rayne Rouce, MD

Baylor College of Medicine

Jennifer Wellman, MS

Akouos

Immediate Past-President

Hans-Peter Kiem, MD, PhD

Fred Hutchinson Cancer Research Center

Molecular Therapy Editor-In-Chief

Roland Herzog, PhD

Indiana University

CEO

David M. Barrett, JD

Seeking Editor-in-Chief for *Molecular Therapy-Methods & Clinical Development*

The American Society of Gene & Cell Therapy (ASGCT) is seeking an Editor-in-Chief for *Molecular Therapy-Methods & Clinical Development*, an official journal of ASGCT and one of the journals in the Molecular Therapy family of journals. ASGCT is the primary professional membership organization for gene and cell therapy. Its members are scientists, physicians, patient advocates, and other professionals and work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies.

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

Overview

The Editor-in-Chief (EIC) is responsible for carrying out the mission of *Molecular Therapy—Methods & Clinical Development* which is publishing important peer-reviewed methods and procedures as well as translational advances in the broad array of fields under the Molecular Therapy umbrella. Focus areas are advances in cell and gene therapy and how they are translated and applied in the clinical setting. Novel methods of gene delivery into immune cells and hematopoietic and other stem cells using integrating, non-integrating vectors, non-viral vectors, and gene editing methods are featured, manufacturing of such products under Good Manufacturing Practice (GMP) conditions, including regulatory science and possible commercialization of these novel products are additional focus areas.

The EIC will maintain the reputation of the journal and attract high-quality submissions. The EIC will be responsible for overseeing a team of Associate Editors and the Editorial Board, ensuring all relevant and scientifically accurate research is considered for publication. The EIC will drive the continued growth of the journal in terms of quality and volume and will establish new initiatives to keep the journal at the leading edge of research. Working with ASGCT and supported by its professional editorial staff, the EIC is expected to provide innovative ideas and thought leadership while following editorial and publishing best practices.

The EIC will be a part-time independent contractor and is expected to serve in the role for a five-year term, beginning January 1, 2024.

Responsibilities

- Undertake responsibility, authority, and accountability for all peer-reviewed editorial content published in the journal and on the journal website. ASGCT recognizes the importance of editorial independence and acknowledges the EIC's sole responsibility for receiving, reviewing, selecting, and approving editorial content for publication in the journal in conjunction with the Editorial team.
- Serve as an ambassador and an advocate for the journal and ASGCT, and represent the journal at scientific and educational events, continuously building relationships within the gene and cell therapy community.
- Oversee the strategic direction of the journal. Assume overall responsibility for maintaining the journal's scientific scope and determining its editorial direction.
- Select, develop, and oversee the appointment and removal of the volunteer editorial leadership of the journal, which may include any combination of assistant editors-in-chief, deputy editors, section editors, and associate editors, as well as an editorial board.
- Ensure expert, rapid, and efficient decisions on manuscripts according to best practices in peer review.
- Implement strategies for increasing the number of high-quality submissions, usage, citations and other measures of success for the journal, in line with ASGCT's publishing strategy.
- Conduct regular editorial meetings to keep the editorial team engaged and updated on performance, metrics, strategies, and journal issues.
- Report on journal performance to the Publications Committee and the Board of Directors

Requirements

- Terminal degree in science or medicine (e.g., Ph.D. or M.D.), with advanced training and experience in gene and cell therapy.
- Strong record of authoring and publishing original research, reviews, commentaries, and editorial manuscripts in the field of gene and cell therapy within peer-reviewed medical and scientific journals.
- Editorial experience as a manuscript reviewer, editorial board member, associate editor, and/or editor-in-chief within a peer-reviewed scientific journal.
- Excellent organizational and interpersonal skills.
- Strong written and oral communication skills.
- Membership within ASGCT.

To apply, please submit your CV and a cover letter outlining relevant experience and your vision for the journal to [ASGCT CEO, David Barrett](#).